MONITORFORHIRE.COM AND OUTCOME SIGN PREFERRED PROVIDER AGREEMENT
Monitor For Hire will provide Outcome with access to more than 2,000 experienced monitors to support the company's project and data management flow for post-approval studies.
PHILADELPHIA – July 27, 2005 – Monitorforhire.com (Monitor For Hire) andOutcome have signed a preferred provider agreement. Monitor For Hire will provide Outcome with access to more than 2,000 experienced monitors tosupport the company's project and data management flow for post-approvalstudies. The relationship will help to globally implement Outcome'sstreamlined approaches to monitoring, targeted specifically to the uniquerequirements of Phase IV work.
"The pressure on pharmaceutical companies to develop reliable evidence inthe post-approval market is particularly strong," said Scott Freedman,president of Monitorforhire.com. "We are excited to help Outcome meet thisdemand by connecting its clients with pre-screened monitors in a variety ofspecialties."
Outcome is the leading provider of post-approval strategies andinformation-based solutions for the pharmaceutical and biotechnologyindustries. Backed by expertise and experience in over 30 therapeutic areas,Outcome has designed, developed and managed an industry leading number ofpost-approval studies, including more than 70 registries and many of thelargest and most well-recognized programs for disease outcomes andsafety/risk management.
"Working with Monitor For Hire to customize its service offering to theunique needs of the post-approval space, we enhance our ability to help ourclients demonstrate the effectiveness, safety and quality of theirproducts," said Richard Gliklich, MD, CEO of Outcome.
About Monitorforhire.com
Monitorforhire.com is the leading web-enabled resource management companyproviding qualified, regional independent clinical monitors to thepharmaceutical, biotechnology, medical device and contract researchindustries. The service allows registered sponsors to query the onlinesystem for pre-qualified, available monitors by therapeutic experience,indication experience and geographic location. Monitor For Hire has morethan 2000 monitors in 28 countries worldwide. Its growing client basecurrently consists of more than 330 clinical sponsors including majorpharmaceutical and biotechnology companies, academic institutions and CROs.Monitor For Hire has offices in Philadelphia, Pa. and San Diego, Calif. Formore information, please visit http://www.monitorforhire.com or call (610)862.0909 on the U.S. East Coast or (858) 4538030 on the West Coast.
About Outcome
Outcome is focused on helping organizations in life sciences and healthcaredevelop evidence, demonstrate effectiveness, manage safety and prove productvalue through registries, Phase IV studies, risk management and coverageunder protocol programs. An Outcome registry received the 2004 InnovationAward from the Department of Health and Human Services. With more than 1.5million patients enrolled in studies powered by Outcome and close to 3,000sites logging on to the Outcome system daily, the Company provides the mostwidely used solutions in the post-approval market. For more information,please visit www.outcome.com.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
